GKOS vs UFPT
GKOS: A commercial-stage ophthalmic medical technology and pharmaceutical company focused on novel, dropless therapies for glaucoma, corneal disorders, and retinal diseases. UFPT: A specialized contract manufacturer producing custom single-use and single-patient medical devices for major OEMs across minimally invasive surgery, wound care, orthopedics, and biopharma applications.
Side-by-side fundamentals
| Metric | GKOS | UFPT | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $166.72 | $248.63 | |
| Market cap as of 2026-08-03 | $9.8B | $1.9B | |
| P/E as of 2026-08-03 | n/a | 28.72 | |
| PEG as of 2026-08-03 | -0.53 | 3.66 | GKOS lower |
| Net margin as of 2026-08-03 | -34.3% | +11.3% | UFPT higher |
| Gross margin as of 2026-08-03 | +78.1% | +28.4% | GKOS higher |
| Operating margin as of 2026-08-03 | -36.0% | +15.2% | UFPT higher |
| ROE as of 2026-08-03 | -26.5% | +16.6% | UFPT higher |
| ROA as of 2026-08-03 | -20.1% | +10.5% | UFPT higher |
| Debt / equity as of 2026-08-03 | 0.10 | 0.31 | GKOS lower |
| Revenue growth (YoY) as of 2026-08-03 | +36.3% | +11.2% | GKOS higher |
| Revenue CAGR (3y) SEC XBRL | +21.5% | +22.7% | UFPT higher |
| Beta as of 2026-08-03 | 1.27 | 1.07 | |
| 1-year return as of 2026-07-31 close | +93.7% | +2.8% | GKOS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.